Business Context and Reporting Period
Company: MiNK Therapeutics, Inc. (INKT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: MiNK is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company's lead candidate, agenT-797, is in Phase 2 trials for solid tumors and critical pulmonary immune failure. The company operates as an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(12.5) million | $(10.8) million |
| Operating Loss | $(12.6) million | $(11.3) million |
| Research & Development Expense | $5.8 million | $6.3 million |
| General & Administrative Expense | $6.7 million | $4.3 million |
| Cash and Cash Equivalents (Year-End) | $13.4 million | $4.6 million |
| Accumulated Deficit | $(156.7) million | $(144.2) million |
| Net Cash Used in Operating Activities | $(5.9) million | $(9.6) million |
| Net Cash Provided by Financing Activities | $14.7 million | $10.8 million |
Note: The company has no revenue. Margins are not applicable.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 16% to $12.5 million in 2025 from $10.8 million in 2024, driven primarily by higher General and Administrative (G&A) expenses.
- G&A Expense Surge: G&A expenses rose 56% to $6.7 million, attributed to increased professional fees and incremental share-based compensation resulting from an option award modification approved in June 2025.
- R&D Expense Decline: R&D expenses decreased 9% to $5.8 million due to timing of clinical trials, reduced pre-clinical activity, and lower personnel costs/headcount.
- Liquidity Improvement: Cash and cash equivalents increased significantly from $4.6 million to $13.4 million, bolstered by $14.5 million in net proceeds from an At-The-Market (ATM) equity offering and a private placement in 2024.
- Debt Repayment: A $5.0 million related-party convertible note issued in 2024 was repaid in full in January 2026 (subsequent event).
Guidance, Outlook, Risks, and Unusual Items
Outlook and Clinical Progress
- agenT-797 (Oncology): Phase 1 data showed durable clinical activity in refractory solid tumors. A Phase 2 investigator-sponsored trial combining agenT-797 with Agenus antibodies (botensilimab/balstilimab) in gastroesophageal cancer is ongoing, with additional data expected in early 2026.
- agenT-797 (Pulmonary): Advancing a randomized Phase 2 adaptive, placebo-controlled trial for severe pneumonia and acute respiratory failure (AHRF) based on prior Phase 1/2 data showing >70% 30-day survival in ARDS patients.
- Pipeline: Preclinical development continues for engineered iNKT programs MiNK-413 (BCMA-CAR-iNKT) and MiNK-215 (FAP-CAR-iNKT).
Risks and Contingencies
- Going Concern: The independent auditor (KPMG LLP) included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management believes current cash plus anticipated funding will satisfy liquidity requirements for more than one year, but additional capital is required.
- Capital Needs: The company expects to incur losses for the foreseeable future and must raise additional capital to fund operations and clinical trials. Failure to do so could force delays or elimination of programs.
- Nasdaq Compliance: The company previously faced delisting risks due to Minimum Value of Listed Securities (MVLS) and bid price requirements but regained compliance in July 2025 following a reverse stock split and market performance.
- Related Party Dependence: The company relies on Agenus Inc. for administrative services, facilities, and certain R&D support. Agenus owns approximately 46% of the outstanding common stock.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $13.4 million cash balance against the projected burn rate and the certainty of "anticipated funding" mentioned in the going concern disclosure.
- ATM Offering Status: Confirm the remaining capacity under the $50.0 million Sales Agreement with B. Riley Securities (approx. $32.0 million remaining as of March 2026) and recent sales activity.
- Clinical Trial Milestones: Monitor the timeline for the Phase 2 AHRF trial readout and the Phase 2 gastroesophageal cancer combination study data expected in early 2026.
- Debt Obligations: Confirm the full repayment of the $5.0 million Agenus convertible note in January 2026 and check for any new debt instruments.
- Share-Based Compensation: Assess the impact of the June 2025 option modification on future G&A expenses and potential dilution.